151 related articles for article (PubMed ID: 16619108)
1. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
Voors AA; van Veldhuisen DJ; van Gilst WH
Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
[No Abstract] [Full Text] [Related]
2. ACE-inhibition for secondary prevention of cardiovascular events--should we change our recommendation after PEACE?
Ferrari R
Cardiovasc Drugs Ther; 2006 Feb; 20(1):11-2. PubMed ID: 16649066
[No Abstract] [Full Text] [Related]
3. Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.
Lonn E; Grewal J
Curr Vasc Pharmacol; 2006 Jul; 4(3):253-68. PubMed ID: 16842143
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
[TBL] [Abstract][Full Text] [Related]
6. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Saha SA; Molnar J; Arora RR
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
[TBL] [Abstract][Full Text] [Related]
7. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
Pierson CA; Epstein BJ; Roberts ME
J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
[No Abstract] [Full Text] [Related]
8. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
9. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
10. [Hypertension in the elderly].
Ogihara T
Nihon Rinsho; 2004 Mar; 62 Suppl 3():394-8. PubMed ID: 15171406
[No Abstract] [Full Text] [Related]
11. Overview of randomised trials of ACE inhibitors.
Remuzzi G; Ruggenenti P
Lancet; 2006 Aug; 368(9535):555-6. PubMed ID: 16905000
[No Abstract] [Full Text] [Related]
12. The role of ACE inhibitor therapy in treating cardiovascular disease.
Flint L
Nurs Times; 2004 Mar 23-29; 100(12):34-7. PubMed ID: 15067910
[TBL] [Abstract][Full Text] [Related]
13. [The long way of angiotensin-converting enzyme inhibitors in the fight against cardiovascular diseases].
Ferrari R; Ambrosio G; Chiariello M
Ital Heart J; 2005 Nov; 6 Suppl 7():3S-4S. PubMed ID: 16485511
[No Abstract] [Full Text] [Related]
14. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
[TBL] [Abstract][Full Text] [Related]
15. ACE inhibitors to prevent cardiovascular events in high-risk patients.
VandeKieft GK
J Fam Pract; 2000 Apr; 49(4):373-4. PubMed ID: 10778846
[No Abstract] [Full Text] [Related]
16. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
Giles TD
Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
[TBL] [Abstract][Full Text] [Related]
17. [HOPE study].
Katayama S
Nihon Rinsho; 2006 Aug; 64 Suppl 6():475-9. PubMed ID: 16983779
[No Abstract] [Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
19. Current indications for ACE inhibitors and HOPE for the future.
Burch S; Ou N
Am J Manag Care; 2002 May; 8(5):478-90; quiz 491-3. PubMed ID: 12019599
[TBL] [Abstract][Full Text] [Related]
20. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
